REG - Cizzle Biotechnology - Marketing Agreement to Enhance Expansion in the US

Cizzle Biotechnology HoldingsAnnouncement

16/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220616:nRSP0535Pa&default-theme=true

RNS Number : 0535P  Cizzle Biotechnology Holdings PLC  16 June 2022

This announcement contains inside information for the purposes of article 7 of
EU Regulation 596/2014 which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018 ("UK MAR").  Upon the publication of
this announcement this inside information is now considered to be within the
public domain.

 

16 June 2022

Cizzle Biotechnology Holdings Plc

 

("Cizzle Biotechnology" or the "Company")

 

Marketing Agreement to Enhance Expansion in the USA

 

Cizzle Biotechnology, the UK based diagnostics developer, is pleased to
announce that it has entered into an agreement with the Behnke Group, a
Texas-based healthcare consulting firm with decades of experience
collaborating with healthcare organizations across the USA and
internationally. The relationship will build on Cizzle Biotechnology's
announcement on 6 May 2022 that it had signed a heads of terms to partner with
CorePath Laboratories ("CorePath"), a full service cancer reference
laboratory, to develop and offer its proprietary early-stage lung cancer test
throughout the USA. The Behnke Group was responsible for identifying and
facilitating the Company's deal with CorePath and the agreement with them is
designed to enhance Cizzle Biotechnology's expansion into the US markets
through the Behnke Group's network of connections in the clinical and
healthcare industry.

Highlights

·    Agreement signed with Behnke Group, USA, to promote, identify and
facilitate partnerships for Cizzle Biotechnology with healthcare providers and
businesses in the USA.

·    The Behnke Group to establish targeted lead generation campaigns to
aid formulating marketing and branding strategies and work with their network
of USA based health systems, clinical diagnostic and pharmaceutical companies.

·    The Behnke Group will work together with CorePath, a Clinical
Laboratory Improvement Amendments ("CLIA") and College of American
Pathologists ("CAP") accredited laboratory, to assist the Company.

Background

Lung cancer is the leading cause of cancer death in the USA, in part because
early-stage lung cancer can be asymptomatic, allowing the disease to progress
and resulting in poor 5-year survival rates*. Currently, there are no simple
specific blood tests to detect lung cancer early when targeted interventions
can improve timely access to cancer care and save lives.

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer. Its technology is based on the ability to detect a stable plasma
biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring
cell nuclear protein involved in DNA replication, and the targeted CIZ1B
variant is highly correlated with early-stage lung cancer.

The Company announced on 6 May 2022 that it had signed a heads of terms with
CorePath to provide the company's CIZ 1B early stage lung cancer test and the
agreement with the Behnke Group now provides Cizzle Biotechnology with access
to a leading-edge healthcare consulting group that focusses specifically on
companies with the most innovative and viable products and services to expand
its presence in the USA.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

"The USA is a strategically important market for us because of the high
prevalence of lung cancer and the resulting loss of life, which could be
improved through the implementation of a simple blood test. We are pleased to
announce the agreement with the Behnke Group, who will help build on our
partnership with CorePath Laboratories who are developing our biomarker into a
certified test, and will use their extensive network with hospitals,
clinicians, and the wider healthcare industry to enhance our presence in the
USA. Together we intend to accelerate the wide adoption of our early-stage
cancer detection technology."

Commenting, Bill Behnke, Founder of The Behnke Group, said:

"I recently attended ASCO22, a major clinical sciences conference in Chicago,
USA, where multiple meetings evidenced considerable interest in Cizzle
Biotechnology's entry into the USA. Cizzle Biotechnology fits perfectly with
the Behnke Group's mission to achieve better outcomes, lower costs and improve
the health and safety of patients. We are excited to add Cizzle Biotechnology
to our portfolio of game changing businesses."

*
https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 33285656
 John Depasquale
 Alex Brearley

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe          cizzle@investor-focus.co.uk
 Florence Chandler

 

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer.  Cizzle Biotechnology is a spin- out from the University of
York, founded in 2006 around the work of Professor Coverley and colleagues.
Its proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

About the Behnke Group

Founded 2005 by healthcare industry business development executive Bill
Behnke, the Behnke Group is an innovative, leading-edge healthcare consulting
group with proven expertise in collaborating with a range of healthcare
organizations in the U.S. and internationally in solving today's most
important business challenges. Focusing on companies with the most innovative
and viable products and services with the potential to improve healthcare,
Bill and his team of experienced healthcare industry professionals provide
affordable, scalable, and sustainable business development strategies that
achieve measurable results for their clients. Please
visit: http://behnkegroup.com
(https://c212.net/c/link/?t=0&l=en&o=3283554-1&h=4272049605&u=http%3A%2F%2Fbehnkegroup.com%2F&a=http%3A%2F%2Fbehnkegroup.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRFAMRTMTJBBPT